Vis AN - Search Results

1

Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy.

Jansen BHE, van Leeuwen PJ, Wondergem M, van der Sluis TM, Nieuwenhuijzen JA, Knol RJJ, van Moorselaar RJA, van der Poel HG, Oprea-Lager DE, Vis AN. Jansen BHE, et al. Among authors: vis an. Eur Urol Oncol. 2021 Oct;4(5):821-825. doi: 10.1016/j.euo.2020.01.002. Epub 2020 Feb 20. Eur Urol Oncol. 2021. PMID: 32088155

2

Prostate cancer detection at low prostate specific antigen.

Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Schröder FH, et al. Among authors: vis an. J Urol. 2000 Mar;163(3):806-12. J Urol. 2000. PMID: 10687982 Clinical Trial.

3

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Schröder FH, et al. Among authors: vis an. Urology. 2001 Jan;57(1):83-90. doi: 10.1016/s0090-4295(00)00863-3. Urology. 2001. PMID: 11164149 Clinical Trial.

4

Recurrence after radical prostatectomy for organ-confined prostate cancer.

Scheepe JR, Vis AN, Mickisch GH. Scheepe JR, et al. Among authors: vis an. Onkologie. 2003 Aug;26(4):330-3. doi: 10.1159/000072090. Onkologie. 2003. PMID: 12972697

5

Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.

van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, Schröder FH. van der Cruijsen-Koeter IW, et al. Among authors: vis an. J Urol. 2005 Jul;174(1):121-5. doi: 10.1097/01.ju.0000162061.40533.0f. J Urol. 2005. PMID: 15947595 Clinical Trial.

6

The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.

Vis AN, Schröder FH, van der Kwast TH. Vis AN, et al. Eur Urol. 2006 Aug;50(2):258-65. doi: 10.1016/j.eururo.2005.11.030. Epub 2006 Jan 6. Eur Urol. 2006. PMID: 16413660

7

Should we replace the Gleason score with the amount of high-grade prostate cancer?

Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH. Vis AN, et al. Eur Urol. 2007 Apr;51(4):931-9. doi: 10.1016/j.eururo.2006.07.051. Epub 2006 Aug 15. Eur Urol. 2007. PMID: 16935413

8

Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.

Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH. Postma R, et al. Among authors: vis an. Eur Urol. 2007 Jul;52(1):89-97. doi: 10.1016/j.eururo.2007.01.030. Epub 2007 Jan 16. Eur Urol. 2007. PMID: 17257742 Clinical Trial.

9

Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort.

Vis AN, Roemeling S, Reedijk AM, Otto SJ, Schröder FH. Vis AN, et al. Eur Urol. 2008 Jan;53(1):91-8. doi: 10.1016/j.eururo.2007.06.001. Epub 2007 Jun 12. Eur Urol. 2008. PMID: 17583416 Clinical Trial.

10

Screening and prostate-cancer mortality in a randomized European study.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Schröder FH, et al. N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18. N Engl J Med. 2009. PMID: 19297566 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page